Research Member Introduction
Biozipcode, Inc., in academic-industry collaboration with Shiga University of Medical Science, has established the “Regenerative Medicine Development Course,” a joint research program led by Professors Hideto Kojima and Takahiko Nakagawa. The company is engaged in pharmaceutical development activities. This joint research program focuses on conducting basic and preclinical research.
- Link to the website of Shiga University of Medical Science, a national university
- The current CEO of Biozipcode, Inc. is Fumihisa Kojima
Hideto Kojima (Research and Development Director)
Advisor & Principal Professor of the Joint Research Program
A diabetes specialist and regenerative medicine researcher. Has long been involved in the complete cure of diabetes, development of cell targeting technologies, and the development of new modalities for cancer treatment.
Takahiko Nakagawa (Co-Research and Developer)
Co-Researcher of the Joint Research Program
A nephrologist, specializing in diabetic nephropathy. Currently, the Head of Nephrology at Rakuhokai Otowa Hospital. Former Associate Professor at the Division of Renal Diseases and Hypertension, University of Colorado, USA.
Joint Research Program “Regenerative Medicine Development Course”
In collaboration with Shiga University of Medical Science, we have established the “Regenerative Medicine Development Course,” a joint research program dedicated to the development of innovative regenerative medical technologies.
In this program, we aim to create a new paradigm in disease treatment by integrating the latest biological insights with advanced engineering techniques. We are particularly focused on repairing and regenerating damaged tissues and organs, and aim to develop customized treatments tailored to individual patients. This initiative brings new hope to the treatment of previously intractable diseases, paving the way for the future of medical care.
Shiga University of Medical Science (National University)
Established in 1974, Shiga University of Medical Science is the only medical university in Shiga Prefecture and is renowned for its commitment to community healthcare. It prides itself on distinctive medical and nursing education aimed at fostering researchers. The university advances unique research utilizing partnerships across academia, industry, and government, specifically in fields such as epidemiology and cutting-edge medical device development, with a focus on elevating the standards of medical technology and healthcare.
Department of Regenerative Medicine Development, Shiga University of Medical Science
The department is dedicated to developing innovative treatments for intractable diseases, including diabetes. Using proprietary techniques from Shiga University of Medical Science, they research strategies for chronic refractory diseases like diabetes, cancer, autoimmune disorders, multi-organ failure, and treatment-resistant conditions. The team is also involved in drug repurposing, new drug development, planning clinical trials, and drafting therapeutic protocols, with the ultimate goal of directly benefiting patients’ treatment.
Biozipcode, Inc.
A venture, originating from Shiga University of Medical Science, Biozipcode is committed to researching diabetes therapeutics. They focus on developing new diagnostic and therapeutic drugs targeting abnormal hematopoietic stem cells that complicate the full recovery from diabetes. Additionally, they provide academic guidance on regenerative medicine and technology and undertake commissioned research on pharmacological trials.
